Status:
UNKNOWN
Argatroban Monitoring in Critically Ill Patients: Evaluation of a Novel Ecarin-based Bedside Test
Lead Sponsor:
Medical University of Vienna
Conditions:
Heparin-induced Thrombocytopenia
Eligibility:
All Genders
18+ years
Brief Summary
Argatroban is a parenteral direct Thrombininhibitor used for anticoagulation in patients suffering from heparin induced thrombocytopenia (HIT). There is increasing evidence suggesting that the activat...
Eligibility Criteria
Inclusion
- Continuous infusion of Argatroban in routine clinical use according to local standard of care
- Expected length of stay at ICU \> 4 days
- 18 years
Exclusion
- Heparin infusion in the last fourhours
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04751357
Start Date
August 1 2020
End Date
June 1 2022
Last Update
February 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna, General Hospital
Vienna, Austria, 1090